MS
Therapeutic Areas
Bicycle Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BT5528 | Solid Tumors (targeting EphA2) | Phase 1/2 |
| BT8009 | Solid Tumors (targeting Nectin-4) | Phase 1/2 |
| BT7480 | Solid Tumors (targeting Nectin-4 & CD137) | Phase 1 |
| BT1718 | Solid Tumors (targeting MT1-MMP) | Phase 1/2a |
| BT7455 | Solid Tumors (targeting EphA2 & CD137) | Preclinical |
| Bicycle Toxin Conjugates (BTCs) | Various Solid Tumors | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Various Solid Tumors | Preclinical/Discovery |
| Bicycle Immune Cell Agonists (BICAs) | Immuno-oncology | Discovery |
Leadership Team at Bicycle Therapeutics
KL
Kevin Lee
Chief Executive Officer
LK
Lee Kalowski
Chief Financial Officer
DS
Dominic Smethurst
Chief Medical Officer
NK
Nicholas Keen
Chief Scientific Officer
AY
Alethia Young
Chief Strategy Officer
AM
Alistair Milnes
Senior Vice President, Business Development